Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * BANK OF AMERICA CORP /DE/ 2. Date of Event Requiring Statement (Month/Day/Year) 09/30/2025 3. Issuer Name and Ticker or Trading Symbol Aptevo Therapeutics Inc. [APVO] (Last) (First) (Middle) BANK OF AMERICA CORPORATE CENTER, 100 N TRYON ST 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) CHARLOTTE, NC 28255 6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock(1)(2)(3) 27 I See Footnotes(1)(2)(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
BANK OF AMERICA CORP /DE/ BANK OF AMERICA CORPORATE CENTER 100 N TRYON ST CHARLOTTE, NC 28255		X
BANK OF AMERICA NA 100 NORTH TRYON STREET CHARLOTTE, NC 28255		X
BOFA SECURITIES, INC. 150 N COLLEGE ST NC1-028-28-04 CHARLOTTE, NC 28255		X

Signatures

/s/ Andres Ortiz, Authorized Signatory for Bank of America Corporation		10/03/2025
**Signature of Reporting Person		Date
/s/ Andres Ortiz, Authorized Signatory for Bank of America N.A.		10/03/2025
**Signature of Reporting Person		Date
/s/ Andres Ortiz, Authorized Signatory for BofA Securities, Inc.		10/03/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The 27 common stock shares ("Shares") reported as acquired in Table I represent Shares of APTEVO THERAPEUTICS INC.("the Issuer") beneficially owned by Bank of America N.A. ("BANA"), and BofA Securities, Inc. ("BOFAS"). BANA and BOFAS are wholly owned subsidiaries of Bank of America Corporation ("Bank of America"). The Reporting Owners may be deemed to have temporarily held voting and dispositive power over additional shares as a result of short-term stock borrowings.
(2)	This statement is jointly filed by Bank of America, BANA and BOFAS. Bank of America holds an indirect interest in the securities listed in Table I ("the Securities") by virtue of its indirect ownership of its subsidiaries, BANA and BOFAS.
(3)	Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer of (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.